18 Feb 2026 | 3 Mins Read
Aurobindo Pharma shares tumble 4% on US FDA quality concerns
Flipitmoney
Aurobindo Pharma Ltd.'s shares declined up to 4% after a US FDA inspection of its Unit-7 facility found multiple lapses in manufacturing, quality control, and record-keeping. The Form 483 highlighted issues including record falsification, unclean equipment, inadequate lab records, and non-compliance with quality procedures.